This article is more than 5 years old. Information may no longer be current.
Dorzolamide more effective than brinzolamide for lowering POAG progression risk, study finds
Acta Ophthalmol. 2010;88(5):541-552.
Click Here to Manage Email Alerts
Primary open-angle glaucoma patients treated with dorzolamide with timolol had half the risk of disease progression compared to patients treated with brinzolamide with timolol, a study showed.
In the 60-month, randomized, evaluator-masked study, 161 primary open-angle glaucoma patients received either dorzolamide 2% or brinzolamide 1%, each in conjunction with timolol 0.5%.
According to multivariate analysis, progression risk was significantly lower in eyes treated with dorzolamide than in eyes treated with brinzolamide.
Researchers identified lower diastolic blood pressure, lower mean arterial pressure, antihypertensive treatment, and lower end diastolic velocity and a higher resistivity index in the ophthalmic artery and short posterior ciliary artery as predictive baseline factors.
"Progression risk decreased by approximately 30% and 20% with each centimeter per second increase of [end diastolic velocity] in the [ophthalmic artery] and [short posterior ciliary artery], respectively, from baseline to the last follow-up visit," according to the study.
In addition, both patient groups showed an approximate 20% increase or decrease in progression risk with each increase or decrease of 0.01 unit of the resistivity index in the ophthalmic artery or short posterior ciliary artery.